prisma software version 9.5.1 (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
prisma software version 9.5.1
Prisma Software Version 9.5.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prisma+software+version+9%2E5%2E1/prism+software/pmc11594578-190-5-8
Average 90 stars, based on 1 article reviews
Prisma Software Version 9.5.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prisma+software+version+9%2E5%2E1/prism+software/pmc11594578-190-5-8
Average 90 stars, based on 1 article reviews
prisma software version 9.5.1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Generated:Article Title: Influence of the Nucleo-Shuttling of the ATM Protein on the Response of Skin Fibroblasts from Marfan Syndrome to Ionizing Radiation Article Snippet: Statistical analyses were performed using Article Title: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors. Article Snippet: PRISM software, version 9.5.1 ( Article Title: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors Article Snippet: PRISM software, version 9.5.1 ( Article Title: Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD. Article Snippet: Article Title: Development of Cas13a-based Assays for Neisseria gonorrhoeae Detection and Gyrase A Determination Article Snippet: We generated all figures in Article Title: Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale Article Snippet: A time-course questionnaire survey using the chemotherapy-induced taste alteration scale (CiTAS) was conducted in patients with advanced urothelial carcinoma (UC) treated with systemic chemotherapy and/or immunotherapy.. A total of 37 patients receiving systemic therapy with enfortumab vedotin (EV), platinum-based chemotherapy and immune checkpoint inhibitors were included in this study.. No significant changes were observed in any of the CiTAS subscales during platinum-based chemotherapy and immune checkpoint inhibitor treatment, while EV therapy induced significant dysgeusia. Article Title: Sex Differences in Sleep Architecture After Traumatic Brain Injury: Potential Implications on Short-Term Episodic Memory and Recovery Article Snippet: Statistical analyses were performed using Article Title: Prediction of Cancer Proneness under Influence of X-rays with Four DNA Mutability and/or Three Cellular Proliferation Assays Article Snippet: Statistical analyses were performed using the Software:Article Title: Influence of the Nucleo-Shuttling of the ATM Protein on the Response of Skin Fibroblasts from Marfan Syndrome to Ionizing Radiation Article Snippet: Statistical analyses were performed using Article Title: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors. Article Snippet: PRISM software, version 9.5.1 ( Article Title: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors Article Snippet: PRISM software, version 9.5.1 ( Article Title: Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD. Article Snippet: Article Title: Development of Cas13a-based Assays for Neisseria gonorrhoeae Detection and Gyrase A Determination Article Snippet: We generated all figures in Article Title: Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale Article Snippet: A time-course questionnaire survey using the chemotherapy-induced taste alteration scale (CiTAS) was conducted in patients with advanced urothelial carcinoma (UC) treated with systemic chemotherapy and/or immunotherapy.. A total of 37 patients receiving systemic therapy with enfortumab vedotin (EV), platinum-based chemotherapy and immune checkpoint inhibitors were included in this study.. No significant changes were observed in any of the CiTAS subscales during platinum-based chemotherapy and immune checkpoint inhibitor treatment, while EV therapy induced significant dysgeusia. Article Title: Sex Differences in Sleep Architecture After Traumatic Brain Injury: Potential Implications on Short-Term Episodic Memory and Recovery Article Snippet: Statistical analyses were performed using Article Title: Prediction of Cancer Proneness under Influence of X-rays with Four DNA Mutability and/or Three Cellular Proliferation Assays Article Snippet: Statistical analyses were performed using the |